Achieve Life Sciences continues to solidify its development and upcoming commercialization of cytisinicline, a smoking cessation drug candidate. The completion of the pivotal ORCA-OL trial in late 2025 reduced R&D expenses but launched a surge in administrative costs linked to commercial readiness. A significant leadership change occurred with Dr. Andrew Goldberg assuming CEO duties in April 2026, signaling an intensified focus on market entry execution. While the company maintains a robust liquidity position with nearly $21 million in cash and a strong current ratio, financial sustainability remains dependent on timely regulatory approval and further financing. The smoking cessation therapy market is competitive and mature, posing both hurdles and opportunities for cytisinicline’s uptake.